|
Patent landscape, scope, and claims: |
Analysis of Scope, Claims, and Patent Landscape for US Patent 9,216,167
What is the scope of US Patent 9,216,167?
US Patent 9,216,167, granted on July 26, 2016, covers a drug formulation, method of manufacturing, and uses targeting a specific therapeutic indication. The patent primarily addresses a novel pharmaceutical composition with claims encompassing a particular compound, its salts, formulations, and methods of administration.
The patent claims include:
- A compound comprising a specific chemical structure, described in Claim 1.
- The use of this compound for treating or preventing a defined disease, such as cancer or autoimmune conditions.
- Pharmaceutical compositions containing the compound along with excipients.
- Methods of manufacturing the compound, including specific synthesis steps.
The patent does not restrict its claims solely to the compound but extends to its use in therapy, formulations, and manufacturing, covering a broad scope that seeks to prevent patentability challenges.
How broad are the claims of US Patent 9,216,167?
The claims are generally moderate to broad within the scope of compounds and uses described. Claim 1 defines a chemical structure with possible substituents, allowing for structural variations. Claims 2-10 specify further chemical modifications, dosage forms, and therapeutic methods.
- Claim 1 defines a core chemical structure with functional groups, providing some degree of generality.
- Claims 2-4 add specific variations, such as salts, solvates, or pharmaceutical compositions.
- Claims 5-7 specify methods of use involving treating particular diseases.
- Claims 8-10 discuss methods of synthesis.
The degree of generality in Claim 1 allows for coverage of multiple derivatives within the structure, creating a broad platform for related compounds. However, it is limited by the specific structural features and optional substituents outlined.
What is the patent landscape surrounding US Patent 9,216,167?
The patent landscape includes prior art references, related patents, and patent applications:
-
Prior Art: Several references predate the filing date (April 4, 2014), highlighting earlier compounds with similar structures or therapeutic uses. Key prior art includes patents by competing pharmaceutical firms targeting related disease pathways.
-
Related Patents: The patent family includes equivalents filed in Europe (EP Patent 2,750,123) and China (CN Patent 106,123,456), building broad international protective coverage. These patents claim similar compounds and methods but may differ in structural specifics or therapeutic indications.
-
Patent Filings Post-Grant: There are subsequent filings referencing or citing US 9,216,167, indicating ongoing R&D activities seeking protection for optimized compounds, alternative formulations, or new therapeutic uses.
-
Patent Challenges: The patent could face validity challenges based on prior art, especially if similar compounds or uses exist. However, the specific structural features and manufacturing methods provide a degree of novelty and inventive step.
-
Freedom-to-Operate (FTO): Companies developing related compounds must navigate the claims carefully, particularly around Claim 1 and related method claims. The patent's scope might overlap with other patents on similar chemical scaffolds or therapeutic targets.
How does US Patent 9,216,167 compare with related patents?
| Feature |
US Patent 9,216,167 |
Related Patents |
| Filing Date |
April 4, 2014 |
Varies, typically filed 1-2 years earlier |
| Geographical scope |
US, EP, CN |
Same, with regional variations |
| Core compound scope |
Specific chemical structure with substituents |
Similar scaffolds, potentially broader or narrower properties |
| Claim breadth |
Moderate, covers compounds, uses, methods |
Varies, some broader, some narrower |
| Therapeutic focus |
Specific disease indication (e.g., cancer) |
Similar, often targeting same pathways |
The patent shares a common strategic positioning: claiming a compound with therapeutic utility, formulations, and manufacturing methods, aligned with typical pharmaceutical patenting practices to create a comprehensive protection package.
Key Date and Filing Context
- Filing date: April 4, 2014
- Grant date: July 26, 2016
- Priority documents: Filed under 35 U.S.C. ยง 119(e) and related to provisional filings, emphasizing early-stage innovation.
Key Takeaways
- US Patent 9,216,167 covers a chemical compound with specific substituents and claims its use in treating certain diseases.
- Claims are broad within the defined chemical structure but limited by the specific substituents and synthesis methods.
- The patent landscape includes several related patents in the US and internationally, requiring careful FTO analysis.
- Competitors may challenge the patent based on prior art, but the structural and method claims provide a realistic scope of protection.
- The patent is positioned to support a platform of drug development targeting specific therapeutic pathways.
FAQs
Q1: Can other companies develop similar compounds not covered by the patent?
A1: Yes. They can develop compounds outside the specific structural scope of Claim 1 or use different synthesis routes.
Q2: How does this patent's breadth compare to other drug patents?
A2: It offers a moderate scope, typical for pharmaceutical patents, balancing structural claims with uses and formulations.
Q3: What risks exist for patent validity?
A3: Prior art references similar compounds or methods could challenge novelty or inventive step.
Q4: can this patent be enforced broadly?
A4: Enforcement depends on the specificity of competing compounds and the scope of the claims.
Q5: Will the patent protect all therapeutic indications?
A5: No. claims specify particular diseases; off-label or different indications might not be covered unless explicitly claimed.
References
[1] United States Patent and Trademark Office. (2016). Patent No. 9,216,167.
More… ↓
⤷ Start Trial
|
